Anti-ischemic Therapy

Chapter
Part of the Current Cardiovascular Therapy book series (CCT)

Abstract

In a simple way, myocardial ischemia is secondary to a disbalance between oxygen supply in relation to the metabolic demands of the myocardium. Figure 1.1 depicts the principal components of this equation. In acute coronary syndromes plaque rupture and thrombosis play a major role, but other factors that decrease oxygen supply or increase myocardial metabolic demands contribute to ischemia and may be the principal cause of acute ischemia in absence of plaque rupture or coronary artery stenosis.

Keywords

Placebo Ischemia Propranolol Verapamil Renin 

References

  1. 1.
    Arnold SV, Morrow D, Ley Y, Cohen DL, Mahoney EM, Braunwald E, Cahn PS. Economic impact of angina after an acute coronary syndrome: insights from the MERLIN-TIMI 36 trial. Circ Cardiovasc Qual Outcomes. 2009;2:344–53.PubMedCrossRefGoogle Scholar
  2. 2.
    López-Sendón J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, Tendera M, Waagstein F, Kiekshus J, Lechat P, Torp-Pedersen C. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The task Force on ACE-inhibitors of the European Society of Cardiology. Eur Heart J. 2004;25:1454–70.PubMedCrossRefGoogle Scholar
  3. 3.
    Waagstein F. Beta-blockers in congestive heart failure: the evolution of a new treatment concept-mechanism of action and clinical implications. J Clin Basic Cardiol. 2002;5:215–23.Google Scholar
  4. 4.
    Frishman WH. Multifactorial actions of beta-adrenergic-blocking drugs in ischemic heart disease: current concepts. Circulation. 1983;67(Suppl I):I-11–8.Google Scholar
  5. 5.
    Hjalmarson Å, Elmfeldt D, Herlitz J, et al. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet. 1981;ii:823–7.CrossRefGoogle Scholar
  6. 6.
    Richterova A, Herlitz J, Holmberg S, et al. The göteborg metoprolol trial in acute myocardial infaction. Effects on chest pain. Am J Cardiol. 1984;53:32D–6.PubMedGoogle Scholar
  7. 7.
    Norris RM, Brown MA, Clarke ED, et al. Prevention of ventricular fibrillation during acute myocardial infarction by intravenous propranolol. Lancet. 1984;2:883–6.PubMedCrossRefGoogle Scholar
  8. 8.
    ISIS-1 (First International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction: ISIS-1. Lancet. 1986;II:57–66.Google Scholar
  9. 9.
    The MIAMI Trial Research Group: Metoprolol in acute myocardial infarction (MIAMI). Am J Cardiol. 1985;56:1G–57.Google Scholar
  10. 10.
    Ryden L, Ariniego R, Arnman K, et al. A double-blind trial of metoprolol in acute myocardial infarction. Effects on ventricular tachyarrhythmias. N Engl J Med. 1983;308:614–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Yusuf S, Lessem J, Pet J, et al. Primary and secondary prevention of myocardial infarction and strokes. An update of randomly allocated controlled trials. J Hypertens. 1993;11 Suppl 4:S61–73.Google Scholar
  12. 12.
    Freemantle N, Cleland J, Young P, et al. Beta blockade after myocardial infarction. Systematic review and meta regression analysis. BMJ. 1999;318:1730–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Roberts R, Rogers WJ, Mueller HS, et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction (TIMI) IIB study. Circulation. 1991;83:422–37.PubMedCrossRefGoogle Scholar
  14. 14.
    Van de Werf F, Janssens L, Brzostek T, et al. Short term effect of early intravenous treatment with beta-adrenergic blocking agents or a specific bradycardia agent in patients with acute myocardial infarction receiving thrombolytic therapy. J Am Coll Cardiol. 1993;2:407–16.CrossRefGoogle Scholar
  15. 15.
    COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo controlled trial. Lancet. 2005;366:1622–32.CrossRefGoogle Scholar
  16. 16.
    Barron HV, Rundle AC, Gore JM, et al., for the Participants in the national registry of myocardial infarction-2. Intracranial hemorrhage rates and effect of immediate beta-blocker use in patients with acute myocardial infarction treated with tissue plasminogen activator. Am J Cardiol. 2000;85:294–8.Google Scholar
  17. 17.
    Pfisterer M, Cox JL, Granger CG, et al. Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction. The GUSTO-I experience. Global utilization of streptokinase and TPA (alteplase) for occluded coronary arteries. J Am Coll Cardiol. 1998;32:634–40.PubMedCrossRefGoogle Scholar
  18. 18.
    The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC guidelines for the management of acutemyocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33:2569–619.CrossRefGoogle Scholar
  19. 19.
    Harjai KJ, Stone GW, Boura J, et al. Effects of prior beta-blocker therapy on clinical outcomes after primary coronary angioplasty for acute myocardial infarction. Am J Cardiol. 2003;91:655–60.PubMedCrossRefGoogle Scholar
  20. 20.
    Halkin A, Nikolsky E, Aymong E, et al. The survival benefit of periprocedural beta-blockers in patients with acute myocardial infarction undergoing primary angioplasty is determined by use of these drugs before admission. Am J Cardiol. 2003;92(Suppl L):228L.Google Scholar
  21. 21.
    Kernis SJ, Arguya KJ, Boura J, et al. Does beta-bloquer therapy improbé clinical outcomes of acute myocardial infarction after successful primary angioplasty? A pooled análisis from the primary angioplasti in myocardial infarction-2 (PAMI-2), No surgery on-site (noSOS), stetn PAMI and Air PAMI trials. Circulation. 2003;108(Suppl IV):416–7.Google Scholar
  22. 22.
    Scheuble A, Emery M, López-Sendón J, de Lopez Sa E, Fondard O, Dabbous OH, Eagle KA, Anderson FA, Steg PG. Patterns of early use of intravenous and oral beta-blockers in ST-segment elevation myocardial infarction in the reperfusion era. The Global Registry of Acute Coronary Events. Eur Heart J. 2005;26(Abstract Suppl):159.Google Scholar
  23. 23.
    Gottlieb S, Weisfeldt ML, Ouyang P, et al. Effect of the addition of propranolol to therapy with nifedipine for unstable angina pectoris: a randomized, double-blind, placebo-controlled trial. Circulation. 1986;3:331–7.CrossRefGoogle Scholar
  24. 24.
    Telford A, Wilson C. Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome. Lancet. 1981;1:1225–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Lubsen JTJ. Effcacy of nifedipine and metoprolol in the early treatment of unstable angina in the coronary care unit: findings from the Holland Interuniversity Nifedipine/metoprolol Trial (HINT). Am J Cardiol. 1987;60:18A–25.PubMedCrossRefGoogle Scholar
  26. 26.
    Yusuf S, Witte J, Friedman L. Overview of results of randomized trials in heart disease: unstable angina, heart failure, primary prevention with aspirin and risk factor modifications. JAMA. 1988;260:2259–63.PubMedCrossRefGoogle Scholar
  27. 27.
    Gottlieb S, McCarter R, Vogel R. Effect of beta-blockade on mortality among high risk patients after myocardial infarction. N Engl J Med. 1998;338:489–97.CrossRefGoogle Scholar
  28. 28.
    Ellis K, Tcheng JE, Sapp S, Topol EJ, Lincoff AM. Mortality benefit of beta blockade in patients with acute coronary syndromes undergoing coronary intervention: pooled results from the Epic, Epilog, Epistent, Capture and Rapport Trials. J Interv Cardiol. 2003;16:299–305.PubMedCrossRefGoogle Scholar
  29. 29.
    Emery M, López-Sendón J, Steg PG, Anderson Jr FA, Dabbous OH, Scheuble A, Eagle KA. Patterns of use and potential impact of early beta-blocker therapy in non-ST-elevation myocardial infarction with and without heart failure: the Global Registry of Acute Coronary Events. Am Heart J. 2006;152:1015–21.PubMedCrossRefGoogle Scholar
  30. 30.
    Tilmant PY, Lablanche JM, Thieuleux FA, et al. Detrimental effect of propranolol in patients with coronary arterial spasm countered by combination with diltiazem. Am J Cardiol. 1983;52:230–3.PubMedCrossRefGoogle Scholar
  31. 31.
    Members of the CAPRICORN Steering Committee on behalf of the investigators and committees. CAPRICORN. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction. Lancet. 2001;357:1385–90.CrossRefGoogle Scholar
  32. 32.
    Church J, Zsotér T. Calcium antagonistic drugs. Mechanism of action. Can J Physiol Pharmacol. 1980;58:254–64.PubMedCrossRefGoogle Scholar
  33. 33.
    The Danish Study Group on Verapamil in Myocardial Infarction. Verapamil in acute myocardial infarction. Eur Heart J. 1984:5;516–28.Google Scholar
  34. 34.
    Gibson RS, Boden WE, Theroux P, Strauss HD, Pratt CM, Gheorghiad M, Capone RJ, Crawford MH, Schlant RC, Kleiger RE. Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. Results of a double-blind, randomized, multicenter trial. N Engl J Med. 1986;315:423.PubMedCrossRefGoogle Scholar
  35. 35.
    Boden W, Gilst W, Scheldewaert R, Starkey S, Carlier M, Julian D, Whitehead A, Bertrand M, Col J, Pedersen O, Lie K, Santoni JP, Fox KM and for the Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis post-Thrombolysis (INTERCEPT). Diltiazem in acute myocardial infarction treated with thrombolytic agents: a randomised placebo controlled trial. Lancet. 2000;355:1751–6.Google Scholar
  36. 36.
    Muller JE, Morrison J, Stone PH, Rude RE, Rosner B, Roberts R, Pearle DL, Turi ZG, Schneider AD, Serfas DH. Nifedipine therapy for patients with threatened and acute myocardial infarction: a randomized, double-blind, placebo-controlled comparison. Circulation. 1984;69:740–7.PubMedCrossRefGoogle Scholar
  37. 37.
    Torfgård KE, Ahlner J. Mechanisms of action of nitrates. Cardiovasc Drugs Ther. 1994;8:701–17.PubMedCrossRefGoogle Scholar
  38. 38.
    Klemenska E, Beresewicz A. Bioactivation of organic nitrates and the mechanism of nitrate tolerance. Cardiol J. 2009;16:11–9.PubMedGoogle Scholar
  39. 39.
    Jugdutt BI, Warnica JW. Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion, and complications. Effect of timing, dosage, and infarct location. Circulation. 1988;78:906–19.PubMedCrossRefGoogle Scholar
  40. 40.
    Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet. 1994;343:1115–22.Google Scholar
  41. 41.
    ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet. 1995;345:669.Google Scholar
  42. 42.
    The ESPRIM trial: short-term treatment of acute myocardial infarction with molsidomine. European Study of Prevention of Infarct with Molsidomine (ESPRIM) Group. Lancet. 1994;344:91–7.Google Scholar
  43. 43.
    Ren Z, Yang Q, Floten HS, Furnary AP, Yim AP, He GW. ATP-sensitive potassium channel openers may mimic the effects of hypoxic preconditioning on the coronary artery. Ann Thorac Surg. 2001;71:642–7.PubMedCrossRefGoogle Scholar
  44. 44.
    Kitakaze M, Asakura M, Kim J, Shintani Y, Asanuma H, Hamasaki T, et al. for the J-WIND Investigators. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet. 2007;370:1483–93.Google Scholar
  45. 45.
    Iwakura K, Ito H, Okamura A, Yasushi Koyama Y, Date M, Higuchi Y, et al. Nicorandil treatment in patients with acute myocardial infarction. A meta-analysis. Circ J. 2009;73:925–31.PubMedCrossRefGoogle Scholar
  46. 46.
    Zaza A, Belardinelli L, Shryock JC. Pathophysiology and pharmacology of the cardiac late sodium current. Pharmacol Ther. 2008;119:326–39.PubMedCrossRefGoogle Scholar
  47. 47.
    Morrow D, Scirica B, Karwatowska E, Murphy E, Budja A, Varshavsky S, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non–ST-elevation acute coronary syndromes he MERLIN-TIMI 36 randomized trial. JAMA. 2007;297:1775–83.PubMedCrossRefGoogle Scholar
  48. 48.
    Wilson S, Scirica B, Braunwald E, Murphy S, Karwatowska E, Buros L, Chaitman B, Morrow D. Observations from the randomized, double-blind, placebo-controlled MERLIN–TIMI(metabolic efficiency with ranolazine for less ischemia in non–ST-segment elevation acute coronary syndromes) 36 trial. J Am Coll Cardiol. 2009;53:1510–6.PubMedCrossRefGoogle Scholar
  49. 49.
    Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme a thiolase. Circ Res. 2000;86:580–8.PubMedCrossRefGoogle Scholar
  50. 50.
    The EMIP-FR Group. European Myocardial Infarction Project--Free Radicals. Effect of 48-h intravenous trimetazidine on short- and long-term outcomes of patients with acute myocardial infarction, with and without thrombolytic therapy; A double-blind, placebo-controlled, randomized trial. Eur Heart J. 2000;18:1537–46.Google Scholar
  51. 51.
    Fox K, Borer JS, Camm AJ, Danchin N, Ferrari R, Lopez-Sendon J, Steg PG, Tardif JC, Tavazzi L, Tendera M. Resting heart rate in cardiovascular disease. J Am Coll Cardiol. 2007;50:823–30.PubMedCrossRefGoogle Scholar
  52. 52.
    Granger CB, Goldberg RJ, Dabbous O, Pieper KS, Eagle KA, Cannon CP, Van de Werf F, Avezum Á, Goodman SG, Flather MD, Fox KAA, for the Global Registry of Acute Coronary Events Investigators. Predictors of hospital mortality in the Global Registry of Acute Coronary Events. Arch Intern Med. 2003;163:2345–53.Google Scholar
  53. 53.
    Yan AT, Yan RT, Tan M, et al. Risk scores for risk stratification in acute coronary syndromes: useful but simpler is not necessarily better. Eur Heart J. 2007;28:1072–8.PubMedCrossRefGoogle Scholar
  54. 54.
    Herman M, Donovan J, Tran M, et al. Use of beta-blockers and effects on heart rate and blood pressure post-acute coronary syndromes: are we on target? Am Heart J. 2009;158:378–85.PubMedCrossRefGoogle Scholar
  55. 55.
    Hjalmarson A, Gilpin EA, Kjekshus J, Chieman G, Nicod P, Henning H, et al. Influence of heart rate on mortality after acute myocardial infarction. Am J Cardiol. 1990;65:547–53.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2014

Authors and Affiliations

  1. 1.Cardiology DepartmentHospital Universitario La Paz, Instituto de Investigación La Paz IdiPazMadridSpain

Personalised recommendations